1. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain.
- Author
-
Grishin EV, Savchenko GA, Vassilevski AA, Korolkova YV, Boychuk YA, Viatchenko-Karpinski VY, Nadezhdin KD, Arseniev AS, Pluzhnikov KA, Kulyk VB, Voitenko NV, and Krishtal OO
- Subjects
- Adenosine Triphosphate pharmacology, Animals, Animals, Newborn, Cells, Cultured, Chondrus, Cytidine Triphosphate pharmacology, Disease Models, Animal, Dose-Response Relationship, Drug, Ganglia, Spinal cytology, Humans, Magnetic Resonance Spectroscopy methods, Membrane Potentials drug effects, Membrane Potentials genetics, Neurogenic Inflammation chemically induced, Neurogenic Inflammation complications, Pain etiology, Patch-Clamp Techniques methods, Purinergic P2 Receptor Antagonists, Rats, Rats, Wistar, Receptors, Purinergic P2 genetics, Receptors, Purinergic P2X3, Sensory Receptor Cells drug effects, Sensory Receptor Cells physiology, Transfection methods, Pain drug therapy, Pain metabolism, Peptides therapeutic use, Receptors, Purinergic P2 metabolism, Spider Venoms chemistry
- Abstract
P2X3 purinoreceptors expressed in mammalian sensory neurons play a key role in several processes, including pain perception. From the venom of the Central Asian spider Geolycosa sp., we have isolated a novel peptide, named purotoxin-1 (PT1), which is to our knowledge the first natural molecule exerting powerful and selective inhibitory action on P2X3 receptors. PT1 dramatically slows down the removal of desensitization of these receptors. The peptide demonstrates potent antinociceptive properties in animal models of inflammatory pain.
- Published
- 2010
- Full Text
- View/download PDF